Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct 3;13(10):2232-2239.
doi: 10.1080/21645515.2017.1342908.

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines

Maria Rosario Z Capeding  1 , Maria Liza Antoinette M Gonzales  2 , Mandeep Singh Dhingra  3 , Naveena Aloysia D'Cor  3 , Venkat Jayanth Midde  3 , Badri Narayan Patnaik  3 , Yaël Thollot  4 , Eric Desauziers  4
Affiliations
Clinical Trial

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines

Maria Rosario Z Capeding et al. Hum Vaccin Immunother. .

Abstract

The killed bivalent (O1 and O139) whole cell oral cholera vaccine (OCV) (Shanchol™) was first licensed in India in 2009 and World Health Organization pre-qualified in 2011. We assessed the safety and immunogenicity of this OCV in the Philippines. This was a phase IV, single-arm, descriptive, open-label study. We recruited 336 participants from 2 centers: 112 participants in each age group (1-4, 5-14 and ≥ 15 years). Participants received 2 OCV doses 14 d apart. Safety was monitored throughout the trial. Blood samples were collected at baseline (pre-vaccination) and 14 d after each dose. Serum vibriocidal antibody titers to V. cholerae O1 (El Tor Inaba and El Tor Ogawa) and O139 strains were assessed, with seroconversion defined as ≥ 4-fold increase from baseline in titers. No immediate unsolicited systemic adverse events/reactions were observed. Unsolicited systemic adverse events were mostly grade 1 intensity. One serious adverse event occurred after the first dose, but was unrelated to vaccination. High seroconversion rates (range 69-92%) were achieved against the O1 serotypes with a trend toward higher rates in the 1-4 y (86-92%) and 5-14 y (86-88%) age groups than the ≥ 15 y age group (69-83%). Lower seroconversion rates were achieved against the O139 serotype (35-70%), particularly in those aged ≥ 15 y (35-42%). The 2-dose regimen of the killed bivalent whole cell OCV was well-tolerated in this study conducted in the Philippines, a cholera-endemic country. Robust immune responses were observed even after a single-dose.

Keywords: Shanchol; The Philippines; cholera vaccine; immunogenicity; safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow of participants through the study. Visit 1 (Day 0), Visit 2 (D14), Visit 3 (D28), Visit 4 (D44) and study completion. Blood samples were drawn at Visit 1, 2 and 3 (n=112 at Visit 1, 2, and 3 for ages 1–4 and 5–14 years; n=112 at Visit 1 and 2, and n=111 at Visit 3 for ≥15 years).
Figure 2.
Figure 2.
Vibriocidal antibody titers and proportion of participants with a ≥ 4-fold rise from baseline (seroconversion) (full analysis set).
See this image and copyright information in PMC

References

    1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9:e0003832. doi:10.1371/journal.pntd.0003832. PMID:26043000 - DOI - PMC - PubMed
    1. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008;2:e173. doi:10.1371/journal.pntd.0000173. PMID:18299707 - DOI - PMC - PubMed
    1. Lopez AL, Macasaet LY, Ylade M, Tayag EA, Ali M. Epidemiology of cholera in the Philippines. PLoS Negl Trop Dis. 2015;9:e3440. doi:10.1371/journal.pntd.0003440. PMID:25569505 - DOI - PMC - PubMed
    1. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, et al.. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine. 2009;27:6887-93. doi:10.1016/j.vaccine.2009.09.008. PMID:19761838 - DOI - PubMed
    1. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, et al.. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5:e1289. doi:10.1371/journal.pntd.0001289. PMID:22028938 - DOI - PMC - PubMed

Publication types

MeSH terms